Supernus Pharmaceuticals reported $1.06B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Abbott USD 50.83B 1.76B Jun/2025
ANI Pharmaceuticals USD 436.76M 18.14M Jun/2025
Aurora Cannabis CAD 588.68M 15.76M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Canopy Growth CAD 488.98M 102.49M Jun/2025
Corcept Therapeutics USD 635.79M 47.49M Jun/2025
Eisai JPY 828.51B 12.91B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Novo Nordisk 168.07B 29.53B Jun/2025
Pacira USD 757.77M 40.77M Jun/2025
Perrigo USD 4.47B 108.3M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Supernus Pharmaceuticals USD 1.06B 33.2M Jun/2025
United Therapeutics USD 7.17B 366.4M Jun/2025
Xeris Pharmaceuticals USD -19300000 10.32M Jun/2025